Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai Plans $80 Million Investment In U.S. Antibody Production

This article was originally published in PharmAsia News

Executive Summary

Eisai's plans to establish a major presence in the United States to develop and market antibody drugs is going to cost the company about $80 million. Part of the funds is to go to building a facility next to its Morphoteck subsidiary in Pennsylvania. Construction is to begin next spring, with the plant coming on-line in fiscal 2012. At first, the plant is to be used to produce antibody drugs for clinical trials, but would upgrade the facility for mass production if needed. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts